Chargement en cours...
The Risks of miRNA Therapeutics: In a Drug Target Perspective
RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs, were approved by the Food and Drug Administration in 2018 and 2019, respectively. However, there is rare news on the advance of miRNA drugs (another therapeutic similar to siRNA drug). Here we report the existing ob...
Enregistré dans:
| Publié dans: | Drug Des Devel Ther |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7910153/ https://ncbi.nlm.nih.gov/pubmed/33654378 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S288859 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|